OptiMed Specialty Pharmacy to Distribute Cosentyx
KALAMAZOO, MI--(Marketwired - April 23, 2016) - OptiMed Specialty Pharmacy has been selected to dispense the limited distribution drug Cosentyx (secukinumab) manufactured by Novartis Pharmaceutical. Cosentyx is a biologic product that is FDA approved to treat adults with any of the following autoimmune inflammatory disorders: moderate to severe plaque psoriasis, active psoriatic arthritis, or active ankylosing spondylitis.
Cosentyx is the first biologic product to target interleukin 17A (IL-17A) in order to reduce inflammation. The drug is given by patient self-injection and is highly effective in improving patient symptoms and enhancing quality of life.
OptiMed Specialty Pharmacy provides patients with specialty medications, like Cosentyx, along with customized patient education, access to financial assistance, and ongoing monitoring and support. These services are delivered by Clinical Pharmacists with advanced training, Licensed Certified Pharmacy Technicians, and critical patient-support service personnel. The pharmacy holds dual specialty pharmacy accreditations from the Accreditation Commission for Health Care (ACHC) and URAC.
"We are excited to have the ability to offer this novel treatment option to our patient and provider partners," said Andy Reeves, owner and CEO of OptiMed Specialty Pharmacy. "OptiMed will provide patients on Cosentyx with patient-centered education, training, monitoring, and support in order to engage them in their health and help them achieve their treatment goals."
Additional information about Cosentyx and Novartis Pharmaceuticals can be found at cosentyx.com.